Verus Capital Partners LLC Has $775,000 Stake in Organon & Co. (NYSE:OGN)

Verus Capital Partners LLC raised its stake in Organon & Co. (NYSE:OGN) by 32.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 51,943 shares of the company’s stock after purchasing an additional 12,750 shares during the quarter. Verus Capital Partners LLC’s holdings in Organon & Co. were worth $775,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. International Assets Investment Management LLC raised its position in Organon & Co. by 1,851.8% in the 3rd quarter. International Assets Investment Management LLC now owns 19,089 shares of the company’s stock valued at $365,000 after buying an additional 18,111 shares during the last quarter. Private Management Group Inc. grew its stake in shares of Organon & Co. by 1.8% in the 3rd quarter. Private Management Group Inc. now owns 1,893,868 shares of the company’s stock worth $36,230,000 after acquiring an additional 34,026 shares in the last quarter. Van ECK Associates Corp raised its holdings in shares of Organon & Co. by 32.2% in the third quarter. Van ECK Associates Corp now owns 276,732 shares of the company’s stock valued at $5,294,000 after purchasing an additional 67,451 shares during the last quarter. M&G PLC lifted its position in shares of Organon & Co. by 4.4% during the third quarter. M&G PLC now owns 204,162 shares of the company’s stock valued at $3,879,000 after purchasing an additional 8,514 shares in the last quarter. Finally, Graypoint LLC boosted its holdings in Organon & Co. by 6.2% during the third quarter. Graypoint LLC now owns 14,555 shares of the company’s stock worth $278,000 after purchasing an additional 853 shares during the last quarter. Institutional investors own 77.43% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have commented on OGN. Morgan Stanley decreased their price objective on shares of Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating for the company in a research note on Friday, February 14th. TD Cowen raised Organon & Co. to a “hold” rating in a report on Wednesday, January 15th. Finally, Barclays dropped their price target on Organon & Co. from $26.00 to $24.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $20.80.

Organon & Co. Stock Down 0.9 %

OGN opened at $14.91 on Friday. Organon & Co. has a twelve month low of $13.87 and a twelve month high of $23.10. The company’s 50-day moving average price is $15.44 and its two-hundred day moving average price is $17.14. The stock has a market cap of $3.84 billion, a price-to-earnings ratio of 4.48, a PEG ratio of 0.90 and a beta of 0.76. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings data on Thursday, February 13th. The company reported $0.83 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.09). Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. The firm had revenue of $1.59 billion during the quarter, compared to analysts’ expectations of $1.57 billion. As a group, equities analysts expect that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 13th. Stockholders of record on Monday, February 24th will be paid a dividend of $0.28 per share. The ex-dividend date is Monday, February 24th. This represents a $1.12 annualized dividend and a dividend yield of 7.51%. Organon & Co.’s payout ratio is 33.63%.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.